Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: Gastrointestinal-sparing potential drugs

Journal of Medicinal Food

Volumn 12, Issue 1, 2009, Pages 208-218

  Singh, Ratan ^a   Kumar, Raj ^a   Singh, D P ^a  

^a JV Jain College   (India)

Author keywords

Cyclooxygenase inhibitor; Gastrointestinal toxicity; Leukotrienes; Nitric oxide; Nitric oxide releasing non steroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANALGESIC AGENT; ANTIPYRETIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; HCT 2035; IBUPROFEN; INDOMETACIN; KETOPROFEN; LICOFELONE; LIPOXYGENASE INHIBITOR; MECLOFENATE SODIUM; MEFENAMIC ACID; NAPROXEN; NCX 701; NITRIC OXIDE; NITRONAPROXEN; NITROPARACETAMOL; NITROXYBUTYLESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALICYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANEMIA; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BONE DISEASE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DYSPEPSIA; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PAPILLA NECROSIS; KIDNEY PERFUSION; LABOR INDUCTION; LIVER TOXICITY; NONHUMAN; PAIN; PEPTIC ULCER; PERITONITIS; PLEURISY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SIDE EFFECT; STOMACH ULCER; STROKE; THROMBOCYTE DYSFUNCTION; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; LEUKOTRIENES; NITRIC OXIDE; PROSTAGLANDINS; PROTECTIVE AGENTS;

EID: 64949188599     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2007.0584     Document Type: Review

References (86)

1. th ed. (Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Gilman AG, eds.), McGraw-Hill, New York, 1996, pp. 617-657.
2. Garner A: Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol 1992;27(Suppl 193):83-89.
3. Lichtenstein DR, Syngal S, Wolfe MM: Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract; the doubleedged sword. Arthritis Rheum 1995;38:5-18.
4. Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-1375.
5. Davies NM, Wallace JL: Nonsteroidal anti-inflammatory drugs-induced gastrointestinal toxicity: new insights into old problems. Gastroenterology 1997;132:127-133.
6. Wallace JL: Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112:1000-1016.
7. Shorrock CJ, Langman M: Nonsteroidal anti-inflammatory drug-induced gastric damage: epidemiology. Dig Dis 1995; 13(Suppl 1):3-8.
8. Singh G, Triadafilopoulus G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(Suppl): 18-24.
9. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340:1888-1899.
10. Pietro M, Maurizio D, Stefania G: NCX-4016 (NO-aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes. Br J Pharmacol 2001;134:905-911.
11. Davies NM, Roseth AG, Wallace JL, et al.: NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997;11:69-79.
12. Downing JEG, Madden JC, Ingram MJ, Rostron C: Gastric and thymic assay of acute oral treatment of rats with nitric oxide esters of ibuprofen or indomethacin. Biochem Biophys Res Commun 2005;26:334;646-653.
13. A. Palmer MA, Piper PJ, Vane JR: Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol 1973;49:226-242.
14. Kuehl FA, Daugherty HW, Ham EA: Interactions between prostaglandins and leukotriene. Biochem Pharmacol 1984; 33:1-5.
15. Cossy J, Belotti D: Synthetic study towards ML 3000, a concise synthesis of this nonsteroidal anti-inflammatory drug. Tetrahedron 1999;55:5145-5156.
16. Laufer SA, Augustin J, Dannhardt G, Kiefer W: (6,7-Di- aryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitor of both cyclooxygenase and 5-lipoxygenase. J Med Chem 1994;37:1894-1897.
17. Rabasseda X, Mealy N, Castaner J: The mechanism of action the new anti-inflammatory compound, ML3000: inhibition of 5-lipoxygenase and COX-1/2. Drugs Future 1995;20:1007-1009.
18. Soll AH, Weinstein WM, Kurata J, McCarthy D: Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-319.
19. Saleeby G, Holt L, Holt S: Pattern and prevention of nonsteroidal anti-inflammatory drug use in complicated peptic ulcer disease (CPUD) [abstract]. Gastroenterology 1991;100:A17.
20. Schoen RT, Vender RJ: Mechanism of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86: 449-458.
21. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino GA: Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107:173-179.
22. Barrachina D, Panés J, Esplugues JV: Role of nitric oxide in gastrointestinal inflammatory and ulcerative diseases: perspective for drugs development. Curr Pharm Des 2001;7:31-48.
23. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino GA: Diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994;257:249-255.
24. Carini M, Aldini G, Stefani R, Orioli M, Facino RM: Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J Pharm Biomed Anal 2001;26:509-518.
25. Asako H, Kubes P, Wallace JL, Gaginella T, Wolf RE, Granger DN: Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipooxygenase products. Am J Physiol 1992;262: 903-908.
26. Asako H, Kubes P, Wallace JL, Wolf RE, Granger DN: Modulation of leukocyte adhesion to rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992;103:146-152.
27. Wallace JL, Vergnolle N, Muscara MN, et al.: Enhanced antiinflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 1999;117:557-566.
28. Jantzen PT, Connor KE, DiCarlo G, et al.: Microglial activation and /3-amyloid deposit reduction caused by a nitric oxide-releasing NSAID in amyloid precursor plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-2254.
29. Jain NK, Patil CS, Kartasamita RE, Decker M, Lehman J, Kulkarni SK: Pharmacological studies on nitro-naproxen (naproxen-2-nitroxyethylester). Drug Dev Res 2004;61:66-78.
30. Clark MJP, Cao TV, Bidhend NM, Cooper D, Gilroy DW: 15-epi-Lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004; 200:69-78.
31. Kitagawa H, Takeda F, Kohei H: Effect of endothelium derived relaxing factor on the gastric lesion induced by HCl in rats. J Pharmacol Exp Ther 1990;253:1133-1137.
32. Mitchell JA, Cirino G, Akarasereenont P, et al.: Flurbinitroxy-butylester: a novel anti-inflammatory drug devoid of ulcerogenic activity inhibits cox-1 and cox-2 [abstract]. Can J Physiol Pharm 1994;72:270.
33. Takaenchi K, Ukawa H, Konaka A, et al.: Effect of nitric oxide releasing aspirin derivative on gastric functional and ul- cerogenic responses in rats, comparison with plain aspirin. J Pharmacol Exp Ther 1998;286:115-121.
34. Cuzzolin L, Conforti A, Adami A, et al.: Anti-inflammatory potency and gastro intestinal toxicity of a new compound NOnaproxen. Pharmacol Res 1995;31:61-65.
35. Wallace JL, Bak K, McKnight W, et al.: COX-1 contributes to inflammatory responses in rats and mice. Implications for GI toxicity. Gastroenterology 1998;115:101-109.
36. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcers healing in rats. Gastroenterology 1995;109:524-530.
37. Alswayeh OA, Clifford RH, Soldato PD, Moore PK: A comparison of anti-inflammatory and antinociceptive activity of nitroaspirin and aspirin. Br J Pharmacol 2000;129:343-350.
38. Donnelly MT, Stack WA, Coutrauld EM, et al.: Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen [abstract]. Gastroenterology 1998;114:107.
39. Muscara MN, McKnight W, Asfaha S, Wallace JL: Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol 2000;129:681-686.
40. Alswayeh OA, Futter LE, Clifford RH, Moore PK: Nitroparac-etamol exhibits anti-inflammatory and antinociceptive activity. Br J Pharmacol 2000;130:1453-1456.
41. Rodomski MW, Palmer RMJ, Moncada S: Comparative pharmacology of endothelium derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92:181-197.
42. Lechi C, Andrioli G, Gaino S, et al.: The antiplatelet effect of a new nitro derivative of acetylsalicylic acid: an in-vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Thromb Haemost 1996;76:791-798.
43. Wallace JL, Muscara MN, McKnight W, et al.: In-vivo an-tithrombotic effects of nitric oxide releasing aspirin derivative, NCX-4016. Thromb Res 1999;93:43-50.
44. Wallace JL, McKnight W, Soldato P, et al.: Antithrombotic effects of a nitric oxide-releasing, gastric-spring aspirin derivative. J Clin Invest 1995;96:2711-2718.
45. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43: 109-142.
46. Rossini G, Berti M, Colonna VD, et al.: Myocardial protection by the nitro derivative of aspirin, NCX 4016: in-vitro and in-vivo experiments in the rabbit. Ital Heart J 2001;1:146-155.
47. Kiraly A, Suto G, Tache Y: Role of nitric oxide in the gastric cytoprotection induced by central vagal stimulation. Eur J Pharmacol 1993;240:299-301.
48. Masuda E, Kawano S, Nagano K, et al.: Endogenous nitric oxide modulates ethanol-induced gastric mucosal injury in rats. Gastroenterology 1995;108:58-64.
49. Muscara MN, Wallace JL: Nitric oxide: therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol 1999;276: G1313-G13166.
50. Reuter BK, Cirino G, Wallace JL: Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 1994;55:PL1-PL8.
51. Wallace JL, Chin BC: New generation NSAID's: the benefit without the risk. Drugs Today 1997;33:371-378.
52. Whittle BJR: Neuronal and endothelium derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol 1993;110:3-17.
53. DelSoldato P, Sorrentino R, Pinto A: NO aspirin: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 1999;20:219-223.
54. Mizuno H, Sakamoto C, Matsuda K, et al.: Induction of cy-clooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-397.
55. Schmassmann A, Peskar BM, Settler C, et al.: Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gas-tro-intestinal ulcer models in rats. Br J Pharmacol 1998;123: 795-804.
56. Wallace JL, Keenan CM, Gale D, Shoupe TS: Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene by synthesis. Gastroenterology 1992;102:18-27.
57. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL: Exacerbation of inflammation associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996;98: 2076-2085.
58. Bonner GF: Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol 2001;96:1306-1308.
59. Wallace JL, Cirino G, McKnight GW, Elliott SN: Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester. Eur J Pharmacol 1995;280:63-68.
60. Fioucci S, Santucci L, Mencarelli A, Del Soldato P, Morelli A: Gastrointestinal safety of a NO-releasing aspirin derivative (NCX4016) in humans: a double blind placebo controlled endoscopic study [abstract]. Gastroenterology 2002;12A:28.
61. Hawkey CJ, Jones IW, Atherton CT, et al.: Gastrointestinal safety of AZD3582: a new chemical entity with a novel multipathway mechanism of action [abstract]. Gastroenterology 2002;122:A54.
62. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs, physiologic foundations and clinical implications. Am J Med 1999;106(Suppl):13S-24S.
63. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatic arthritis. N Engl J Med 2000;343:1520-1528.
64. Merck: COX-2 cardiovascular safety studies will enroll 30,000 subjects; data will address "lingering concerns." The Pink Sheet 2001;63:51.
65. Busija DW, Thore C, Beasley T, Bari F: Induction of cyclooxygenase-2 following anoxic stress in piglet cerebral arteries. Microcirculation 1996;3:379-386.
66. Dowd NP, Scully M, Addreley SR, Cunningham AJ, Fitzgerald DJ: Inhibition of COX-2 aggravates doxorubicin-mediated cardiac injury in-vivo. J Clin Invest 2001;108:585-590.
67. Guo Y, Bao W, Sinmura WJ, Wu K, Tang XL, Bolli R: Evidence for an essential role of cycloxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol 2000;95:479-484.
68. Hennan JK, Huang J, Barrett TD, et al.: Effects of selective cycloxygenase-2 inhibition on vascular responses and thrombosis in coronary arteries. Circulation 2001;104:820-825.
69. Shinmura K, Tang XL, Wang Y, et al.: Cyclooxygenase-2 mediates the cardioprotective effect of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000;97:10197-10202.
70. Rossoni G, Muscara MN, Cirino G, Wallace JL: Inhibition of cyclooxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol 2002;135:1540-1546.
71. 2. Science 2002; 296:539-541.
72. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
73. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of EDRF. Nature 1987;327: 524-526.
74. Radomski MW, Palmer RMJ, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-1489.
75. Radomski MW, Palmer RMJ, Moncada S: The anti-aggregating properties of vascular endothelium interactions between prosta-cyclin and nitric oxide. Br J Pharmacol 1987;92:639-645.
76. Garg UC, Hassis A: Nitric oxide-generating vasodilator and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultural rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
77. Linder L, Kiowski W, Buhler F, Lusher T: Indirect evidence for the release of endothelium derived relaxing factor in human forearm circulation in-vivo. Blunted response in essential hypertension. Circulation 1990;81:1762-1767.
78. Panza JA, Casino PR, Kileoyne CM, Quyyami AA: Role of endothelium derived nitric oxide in the abnormal endothelium de- pendent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-1474.
79. Katz S, Biasucci L, Sabba C, et al.: Impaired endothelium-me- diated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992;19:918-925.
80. Kubo S, Rector T, Bank A, Williams R, Heifetz S: Endothelium dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-1596.
81. Greglewski RJ, Moncada S, Palmer RMJ: Super oxide anion is involved in the breakdown of EDRF. Nature 1986;320: 454-456.
82. Cannon RO: Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998;44:1809-1819.
83. Paul-Clark MJ, Mancini L, Del Soldato P, Flower RJ, Perreti M: Potent anti arthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A 2002;99:1677-1682.
84. Paul-Clark M, Del Soldato P, Fiorucci S, Flower RJ, Perretti M: 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol 2000;131:1345-1354.
85. Futter LE, Al-Swayeh OA, Moore PK: A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br J Pharmacol 2001;132:10-12.
86. Fiorucci S, Antonelli E, Mencarelli A, et al.: A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol 2002;135: 589-599.